Refilins: A link between perinuclear actin bundle dynamics and mechanosensing signaling

Actin cytoskeleton dynamics lie at the heart of cell mechanosensing signaling. In fibroblast cells, two perinuclear acto-myosin structures, the actin cap and the transmembrane actin-associated nuclear (TAN) line, are components of a physical pathway transducing extracellular physical signals to changes in nuclear shape and movements. We recently demonstrated the existence of a previously uncharacterized third apical perinuclear actin organization in epithelial cells that forms during epithelial–mesenchymal transition (EMT) mediated by TGFβ (TGFβ). A common regulatory mechanism for these different perinuclear actin architectures has emerged with the identification of a novel family of actin bundling proteins, the Refilins. Here we provide updates on some characteristics of Refilin proteins, and we discuss potential function of the Refilins in cell mechanosensing signaling

Minor salivary gland tumors : a clinicopathological study of 18 cases

Introduction: Minor salivary gland tumors (MSGTs) are infrequent, representing 10-15% of all salivary neoplasms. Despite this low frequency, MSGTs conform a heterogeneous group of neoplasms characterized by a broad range of histological types. Patients and method: We identified cases of MSGT in a retrospective study of the biopsies made in the period 1997-2007 in the Service of Oral Surgery (Dental Clinic of the University of Barcelona, Spain). The data collected comprised patient age and sex, the clinical characteristics and location of the tumor, the duration of the lesion, its size, the treatment provided, and the histopathological findings. Results: Of the 18 cases of MSGT studied, 12 corresponded to women (66.7%) and 6 to men (33.3%). The great majority (94.4%) were benign tumors. The preferential location was the posterior third of the hard palate (33.2%), followed by the soft palate (16.7%) and the mucosa of the upper lip (16.7%). The histopathological diagnoses of our MSGTs comprised 10 pleomorphic adenomas (55.3%), 2 cystadenomas (11.1%), 1 myoepithelioma (5.6%), 1 sialadenoma papilliferum (5.6%), 1 basal cell adenoma (5.6%), 1 Warthin?s tumor (5.6%), 1 canalicular adenoma (5.6%), and 1 low-grade polymorphic adenocarcinoma (5.6%). Discussion and conclusions: Coinciding with our own results, the literature describes a high recurrence rate for MSGTs (5-30%) when surgical removal is incomplete. Six percent of all benign minor salivary gland tumors are considered to relapse, versus 65% of all malignant lesions. Periodic clinical controls are required, since the possibility of malignant transformation must be taken into account

Integrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature

Primary Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study, we confirmed a vast coordinated hypomethylation and overexpression effects in IFN-related genes, what is known as the IFN signature. Stratified and conditional analyses suggest a strong interaction between SS-associated HLA genetic variation and the presence of Anti-Ro/SSA autoantibodies in driving the IFN epigenetic signature and determining SS. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified potential new genetic variants associated with SS that might mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, autoantibody profiles, DNA methylation and gene expression in SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Caractérisation d'une nouvelle famille de protéines régulatrices des réseaux périnucléaires d'actine, les Refilines. Interaction avec la Filamine A et implication dans le remodelage du noyau cellulaire

The actin cytoskeleton is a highly dynamic structure involved in cell signaling and that creates mechanical force for the completion of diverse functions such as adhesion, migration, division or differentiation. Proteins that regulate this structure can modulate its function. We identified a new protein family that regulates the actin cytoskeleton, Refilin proteins (RefilinA and RefilinB), and whose expression correlates with differentiation switches. RefilinA is induced during differentiation of neural multipotent precursors into glial progenitors, while RefilinB is stabilized in epithelial cells during epithelial-mesenchymal transition (EMT) induced by TGF-β. In cells, Refilins interact with FilaminA, a protein that binds actin filaments to organize them into a network. Genetic syndromes where the FilaminA gene is mutated lead to important developmental defects, The Refilin/FilaminA complex generates actin cables as well as a new perinuclear structure called « actin cap » or «TAN line» that interacts with the nuclear envelope to regulate nuclear movement and shape. Refilin proteins are the only proteins identified so far that induce the formation of perinuclear actin structures. These results open up new perspective for the understanding of FilaminA's function as well as for the biology and functions of perinuclear actin structures.Le cytosquelette d'actine est une structure dynamique capitale pour la cellule, qui intervient dans les processus de signalisation et génère des forces mécaniques pour compléter des fonctions aussi diverses que l'adhésion, la migration, la division ou la différenciation. Les protéines qui régulent cette structure sont capables de moduler ces fonctions. J'ai identifié une nouvelle famille de protéines régulatrices de l'actine, les protéines Refilines (RefilineA et RefilineB), dont l'expression est corrélée avec l'engagement des cellules dans des programmes de différenciation. La RefilineA est induite lors de la différenciation des cellules précurseurs neurales multipotentes en cellules progénitrices gliales. La RefilineB est stabilisée dans les cellules épithéliales lors de la transition épithélio-mésenchymateuse (TEM) induite par le TGF-β. Dans ces cellules, les Refilines agissent en se complexant à la FilamineA, une protéine qui se lie aux filaments d'actine et forme le maillage. Des syndromes génétiques de mutations sur le gène de la FilamineA entrainent d'importants défauts développementaux, cependant la fonction précise de la protéine reste à ce jour obscure. Le complexe Refiline/FilamineA induit la formation de câbles d'actine et génère également une nouvelle structure d'actine périnucléaire appelée coiffe d'actine (« actin cap ») ou « ligne TAN» qui s'ancre à l'enveloppe nucléaire pour réguler les mouvements et la morphologie du noyau. Les Refilines sont les seules protéines identifiées à ce jour capables de catalyser la formation de structures périnucléaires d'actine. Ces résultats ouvrent donc de nouvelles perspectives pour appréhender les fonctions de la FilamineA ainsi que la biologie et les fonctions des structures périnucléaires d'actine

Characterisation of Refilin proteins that regulate perinuclear actin structures. Interaction with FilaminA and role in nuclear remodelling.

Le cytosquelette d'actine est une structure dynamique capitale pour la cellule, qui intervient dans les processus de signalisation et génère des forces mécaniques pour compléter des fonctions aussi diverses que l'adhésion, la migration, la division ou la différenciation. Les protéines qui régulent cette structure sont capables de moduler ces fonctions. J'ai identifié une nouvelle famille de protéines régulatrices de l'actine, les protéines Refilines (RefilineA et RefilineB), dont l'expression est corrélée avec l'engagement des cellules dans des programmes de différenciation. La RefilineA est induite lors de la différenciation des cellules précurseurs neurales multipotentes en cellules progénitrices gliales. La RefilineB est stabilisée dans les cellules épithéliales lors de la transition épithélio-mésenchymateuse (TEM) induite par le TGF-β. Dans ces cellules, les Refilines agissent en se complexant à la FilamineA, une protéine qui se lie aux filaments d'actine et forme le maillage. Des syndromes génétiques de mutations sur le gène de la FilamineA entrainent d'importants défauts développementaux, cependant la fonction précise de la protéine reste à ce jour obscure. Le complexe Refiline/FilamineA induit la formation de câbles d'actine et génère également une nouvelle structure d'actine périnucléaire appelée coiffe d'actine (« actin cap ») ou « ligne TAN» qui s'ancre à l'enveloppe nucléaire pour réguler les mouvements et la morphologie du noyau. Les Refilines sont les seules protéines identifiées à ce jour capables de catalyser la formation de structures périnucléaires d'actine. Ces résultats ouvrent donc de nouvelles perspectives pour appréhender les fonctions de la FilamineA ainsi que la biologie et les fonctions des structures périnucléaires d'actine.The actin cytoskeleton is a highly dynamic structure involved in cell signaling and that creates mechanical force for the completion of diverse functions such as adhesion, migration, division or differentiation. Proteins that regulate this structure can modulate its function. We identified a new protein family that regulates the actin cytoskeleton, Refilin proteins (RefilinA and RefilinB), and whose expression correlates with differentiation switches. RefilinA is induced during differentiation of neural multipotent precursors into glial progenitors, while RefilinB is stabilized in epithelial cells during epithelial-mesenchymal transition (EMT) induced by TGF-β. In cells, Refilins interact with FilaminA, a protein that binds actin filaments to organize them into a network. Genetic syndromes where the FilaminA gene is mutated lead to important developmental defects, The Refilin/FilaminA complex generates actin cables as well as a new perinuclear structure called « actin cap » or «TAN line» that interacts with the nuclear envelope to regulate nuclear movement and shape. Refilin proteins are the only proteins identified so far that induce the formation of perinuclear actin structures. These results open up new perspective for the understanding of FilaminA's function as well as for the biology and functions of perinuclear actin structures